Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial (Q58215230)

5

0 references

author name string

Chia-Chi Lin

1

0 references

Chiun Hsu

2

0 references

Wei-Ling Hsu

4

0 references

Chih-Hsin Yang

Investigational New Drugs

6

0 references

publication date

26 August 2006

0 references

published in

0 references

volume

25

0 references

issue

1

0 references

page(s)

77-84

0 references

cites work

A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.

1 reference

Crossref

https://api.crossref.org/works/10.1007/S10637-006-9004-9

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

12 December 2020

Prognosis of hepatocellular carcinoma: the BCLC staging classification

1 reference

12 December 2020

Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis.

1 reference

12 December 2020

Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system.

1 reference

12 December 2020

Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown

1 reference

12 December 2020

Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients

1 reference

12 December 2020

Antitumor effect of arsenic trioxide in murine xenograft model

1 reference

12 December 2020

[Arsenic trioxide in the treatment of advanced primary liver and gallbladder cancer]

1 reference

12 December 2020

Optimal two-stage designs for phase II clinical trials

1 reference

12 December 2020

Inhibition by arsenic trioxide of human hepatoma cell growth

1 reference

12 December 2020

Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies

1 reference

12 December 2020

Early recognition of hepatocellular carcinoma

1 reference

12 December 2020

Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide

1 reference

12 December 2020

Arsenic trioxide induces apoptosis of rat hepatocellular carcinoma cells in vivo

1 reference

12 December 2020

A phase II trial of arsenic trioxide in patients with metastatic melanoma

1 reference

12 December 2020

Effect of Arsenic Trioxide on QT Interval in Patients With Advanced Malignancies

1 reference

12 December 2020

Alpha-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma

1 reference

12 December 2020

Low-dose thalidomide treatment for advanced hepatocellular carcinoma

1 reference

12 December 2020

A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients

1 reference

12 December 2020

Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy

1 reference

12 December 2020

Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma

1 reference

12 December 2020

Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma

1 reference

12 December 2020

Recent advances in non-surgical treatment for advanced hepatocellular carcinoma

1 reference

12 December 2020

Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis

1 reference

12 December 2020

Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells

1 reference

12 December 2020